Mark P. Ettinger

4.5k total citations · 1 hit paper
30 papers, 3.4k citations indexed

About

Mark P. Ettinger is a scholar working on Orthopedics and Sports Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Mark P. Ettinger has authored 30 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Orthopedics and Sports Medicine, 21 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Mark P. Ettinger's work include Bone health and osteoporosis research (23 papers), Bone health and treatments (21 papers) and Bone Metabolism and Diseases (7 papers). Mark P. Ettinger is often cited by papers focused on Bone health and osteoporosis research (23 papers), Bone health and treatments (21 papers) and Bone Metabolism and Diseases (7 papers). Mark P. Ettinger collaborates with scholars based in United States, Canada and Denmark. Mark P. Ettinger's co-authors include David L. Kendler, David A. Hanley, Howard S. Barden, Richard B. Mazess, Paul D. Miller, Michael A. Bolognese, Stuart Weiss, Kristel Vandormael, Eric Orwoll and R Lorenc and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Mark P. Ettinger

29 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alendronate for the Treatment of Osteoporosis in Men

2000 689 citations Eric Orwoll, Mark P. Ettinger et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark P. Ettinger United States	23	2.3k	1.8k	966	731	342	30	3.4k
P. Vestergaard Denmark	16	1.2k 0.5×	686 0.4×	796 0.8×	344 0.5×	447 1.3×	21	2.4k
Yu Z. Bagger Denmark	28	1.4k 0.6×	751 0.4×	984 1.0×	346 0.5×	390 1.1×	45	3.1k
D. Thiébaud Switzerland	32	1.1k 0.5×	1.4k 0.8×	633 0.7×	360 0.5×	1.1k 3.1×	73	3.2k
Kristine D. Harper United States	23	1.6k 0.7×	1.0k 0.6×	913 0.9×	683 0.9×	166 0.5×	37	3.1k
N. H. Bjarnason Denmark	18	1.4k 0.6×	1.2k 0.7×	793 0.8×	286 0.4×	272 0.8×	31	3.1k
Ombretta Di Munno Italy	29	1.2k 0.5×	640 0.4×	577 0.6×	374 0.5×	217 0.6×	58	2.6k
Margaret C. Evans New Zealand	20	1.3k 0.6×	441 0.2×	404 0.4×	320 0.4×	333 1.0×	30	2.2k
Nigel Gilchrist New Zealand	22	1.0k 0.4×	755 0.4×	546 0.6×	508 0.7×	173 0.5×	70	2.0k
Shailaja Suryawanshi United States	16	1.1k 0.5×	1.2k 0.7×	1.1k 1.1×	982 1.3×	227 0.7×	28	3.6k
Arkadi Chines United States	43	4.5k 1.9×	3.5k 2.0×	2.1k 2.2×	614 0.8×	204 0.6×	102	6.5k

Countries citing papers authored by Mark P. Ettinger

Since Specialization

Citations

This map shows the geographic impact of Mark P. Ettinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark P. Ettinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark P. Ettinger more than expected).

Fields of papers citing papers by Mark P. Ettinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark P. Ettinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark P. Ettinger. The network helps show where Mark P. Ettinger may publish in the future.

Co-authorship network of co-authors of Mark P. Ettinger

This figure shows the co-authorship network connecting the top 25 collaborators of Mark P. Ettinger. A scholar is included among the top collaborators of Mark P. Ettinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark P. Ettinger. Mark P. Ettinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Greenspan, Susan L., Henry G. Bone, Mark P. Ettinger, et al.. (2007). Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis. Annals of Internal Medicine. 291 indexed citations

McClung, Michael R., Ethel S. Siris, Steve Cummings, et al.. (2006). Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause The Journal of The North American Menopause Society. 13(3). 377–386. 77 indexed citations

Emkey, Ronald & Mark P. Ettinger. (2006). Improving Compliance and Persistence with Bisphosphonate Therapy for Osteoporosis. The American Journal of Medicine. 119(4). S18–S24. 65 indexed citations

Ettinger, Mark P., et al.. (2006). Medication Persistence With Weekly Versus Daily Doses of Orally Administered Bisphosphonates. Endocrine Practice. 12(5). 522–528. 50 indexed citations

Chesnut, Charles H., Mark P. Ettinger, Paul D. Miller, et al.. (2005). Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Current Medical Research and Opinion. 21(3). 391–401. 75 indexed citations

Hodsman, Anthony B., David A. Hanley, Mark P. Ettinger, et al.. (2004). Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis. Obstetrical & Gynecological Survey. 59(5). 356–358. 7 indexed citations

Miller, Paul D., Thomas J. Schnitzer, Ronald Emkey, et al.. (2004). Weekly Oral Alendronic Acid in Male Osteoporosis. Clinical Drug Investigation. 24(6). 333–341. 30 indexed citations

Recker, Robert R., J. A. Stakkestad, C. H. Chesnut, et al.. (2004). Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone. 34(5). 890–899. 142 indexed citations

Ettinger, Mark P.. (2003). Aging Bone and Osteoporosis. Archives of Internal Medicine. 163(18). 2237–2237. 127 indexed citations

10.

Ettinger, Mark P., Thomas Littlejohn, Sherwyn Schwartz, et al.. (2003). Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study.. PubMed. 289(14). 1826–32. 151 indexed citations

11.

Dujovne, Carlos A., Mark P. Ettinger, J. Frederick McNeer, et al.. (2002). Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. The American Journal of Cardiology. 90(10). 1092–1097. 297 indexed citations

12.

Taggart, Hugh, Michael A. Bolognese, Robert Lindsay, et al.. (2002). Upper Gastrointestinal Tract Safety of Risedronate: A Pooled Analysis of 9 Clinical Trials. Mayo Clinic Proceedings. 77(3). 262–270. 82 indexed citations

13.

Harris, Steven T., Erik Fink Eriksen, Michael Davidson, et al.. (2001). Effect of Combined Risedronate and Hormone Replacement Therapies on Bone Mineral Density in Postmenopausal Women¹. The Journal of Clinical Endocrinology & Metabolism. 86(5). 1890–1897. 105 indexed citations

14.

Downs, Robert W., Norman H. Bell, Mark P. Ettinger, et al.. (2000). Comparison of Alendronate and Intranasal Calcitonin for Treatment of Osteoporosis in Postmenopausal Women. Obstetrical & Gynecological Survey. 55(10). 628–629. 13 indexed citations

15.

Miller, Paul D., Grattan C. Woodson, Angelo A. Licata, et al.. (2000). Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clinical Therapeutics. 22(12). 1433–1442. 43 indexed citations

16.

Orwoll, Eric, Mark P. Ettinger, Stuart Weiss, et al.. (2000). Alendronate for the Treatment of Osteoporosis in Men. New England Journal of Medicine. 343(9). 604–610. 689 indexed citations breakdown →

17.

Downs, Robert W., Norman H. Bell, Mark P. Ettinger, et al.. (2000). Comparison of Alendronate and Intranasal Calcitonin for Treatment of Osteoporosis in Postmenopausal Women*. The Journal of Clinical Endocrinology & Metabolism. 85(5). 1783–1788. 75 indexed citations

18.

Rittmaster, Roger S., Michael A. Bolognese, Mark P. Ettinger, et al.. (2000). Enhancement of Bone Mass in Osteoporotic Women with Parathyroid Hormone followed by Alendronate¹. The Journal of Clinical Endocrinology & Metabolism. 85(6). 2129–2134. 230 indexed citations

19.

Mazess, R. B., Howard S. Barden, J. Vetter, & Mark P. Ettinger. (1989). Advances in noninvasive bone measurement. Annals of Biomedical Engineering. 17(2). 177–181. 12 indexed citations

20.

Mazess, Richard B., Howard S. Barden, & Mark P. Ettinger. (1988). Radial and spinal bone mineral density in a patient population. Arthritis & Rheumatism. 31(7). 891–897. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact